Invest in the Future of Diagnostic Solutions
We are building a tool ready to make diagnostic evaluation for autism faster, more accurate and cheaper.
Are you a current BlinkLab shareholder?
Access our comprehensive stock charts, recent announcements, and additional resources.
BlinkLab Dx 1 is a smartphone-based platform seeking FDA 510(k) clearance. Our goal is to aid clinicians and empower parents in detecting developmental concerns early, ultimately improving outcomes for children.
Call for action
Autism prevalence has surged over 2% among children, according to the CDC and WHO.
The challenge
Governments and healthcare providers are urgently seeking new technologies to accelerate diagnostics, enhance accuracy, and reduce medical costs.
Our solution
BlinkLab is at the forefront, delivering a neuroscience-powered, tech-driven, and accessible solution designed to facilitate early diagnosis in young children.
Watch the interview with Brian Leedman, chair of our board.
Our stock
BlinkLab ASX:BB1
-
-
-
BlinkLab in the Media
Read the latest media coverage of BlinkLab's most recent clinical and corporate developments.
.jpeg)
.png)
Our pipeline
Our R&D pipeline is focused on securing FDA 510(k) clearance and EU regulatory approval for BlinkLab Dx 1 as a diagnostic adjunct for autism and ADHD, positioning it as a transformative tool for early detection.
BlinkLab’s product pipeline reflects a staged approach to clinical validation for autism and ADHD, regulatory engagement, and post-authorization monitoring, enabling commercialization in line with FDA requirements for software as a medical device (SaMD).
Meet our team!
BlinkLab is a diverse team of neuroscientists, software developers, medical doctors, and other experts. Together, we work to advance the assessment of neurodevelopmental conditions.
"For me, it's gratifying to apply neuroscience for improving autism and ADHD diagnosis and care."
Dr. Henk-Jan Boele, co-founder of BlinkLab, leads a team of neuroscientists, medical doctors, and software developers to bring this mission to life. Founded as a Princeton University startup in 2021, BlinkLab went public on the ASX (ASX:BB1) in April 2024 and is now seeking FDA clearance for its first two diagnostic products:
BlinkLab Dx 1 – Diagnostic Aid Supporting Autism Assessment
FDA 510(k) Regulatory Program Currently Underway
BlinkLab Dx 2 – Diagnostic Aid Supporting ADHD Assessment
Clinical Feasibility Studies Currently in Preparation
(Co-Founder, Managing Director & CEO)
ASX announcements
%20SMALL.jpg)
Awesome! You're now signed up.
You will receive our newsletter. You can opt out via the newsletter.